Search results: (10000)
News EHL preparations have the potential to change the quality of life for people with hemophilia
Within the therapeutic modalities for hemophilia, the current era offers a number of preparations. Newer extended half-life (EHL) replacement therapies can provide hemophiliacs with better protection against bleeding and allow for greater physical activity.
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Three tests to confirm the diagnosis of acquired hemophilia – infographic
Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.5 In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.4
News Position of Parenteral Therapy in Patients with Severe COVID-19 Disease
Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency requiring non-invasive or invasive pulmonary ventilation. Intensive care therapy is associated with a high risk of severe malnutrition. According to current recommendations by the European Society for Clinical Nutrition and Metabolism, parenteral therapy plays an important role in the nutrition of patients.
News Transthyretin Amyloidosis in Patients with Carpal Tunnel Syndrome
Carpal tunnel syndrome is considered a warning sign for cardiac amyloidosis. Amyloid deposits are often found in the tenosynovial material removed during surgery. However, the prevalence of concomitant cardiomyopathy is not yet fully understood. Japanese researchers from Kumamoto University recently focused on the relationship between carpal tunnel syndrome and cardiac amyloidosis in their newly published prospective study.
News Subcutaneous vs. Intravenous Immunoglobulins in Patients with CLL
Secondary antibody immunodeficiency is a common complication in patients with chronic lymphocytic leukemia (CLL), and infections, along with secondary malignancies, are the leading cause of death in these patients. Hypogammaglobulinemia can be managed with immunoglobulin replacement therapy (IGRT). Besides the classic intravenous form (IVIG), a subcutaneous form (SCIG) is also available. An Italian retrospective study published in the journal Current Oncology compared their efficacy in secondary immunodeficiency in CLL patients.
News Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
In the treatment of metastatic colorectal cancer (mCRC), prognostic factors besides overall survival (OS) and progression-free survival (PFS) include early tumor regression (ETS) and depth of response (DpR). Japanese authors presented the results of an analysis at the European Society for Clinical Oncology (ESMO) congress in September 2022, which evaluated the correlation between ETS, DpR, and OS/PFS in patients with wild-type RAS mCRC from the PARADIGM study.
News Current Recommendations of the Expert Panel on the Management of von Willebrand Disease
Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new recommendations from 2021 regarding the care of people with vWD are evidence-based and supported by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation USA (NHF), and the World Federation of Hemophilia (WFH). We bring you a concise summary of the key points.
News Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?
News RETRO-TAS Study – Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice
How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.
News Study TACTIC – Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice
In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with trifluridine/tipiracil (FTD/TPI) was associated with improved overall survival and progression-free survival in pre-treated metastatic colorectal cancer (mCRC) patients. The below-presented TACTIC study provides prospective data from German real-world practice.
News INFOGRAPHIC: Migraine Treatment Without Mistakes
A practical guide on how to proceed with the diagnosis of migraine, so that the treatment is effective and tailored to the patient.
News Thinking About Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is one of the most prognostically severe and difficult-to-treat lung diseases. It affects about 5 million people worldwide, with an estimated incidence in the Czech Republic of 1/100,000 inhabitants. Although it is a relatively rare disease, due to its high mortality rate (the median survival of untreated patients is 2−3 years), it is essential to have a basic awareness of the possible symptoms of IPF. Expert sources even state that, according to statistics, only pancreatic cancer leads to a faster death compared to untreated pulmonary fibrosis.
News Prophylaxis with Enoxaparin After Total Knee or Hip Replacement
Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study evaluated the incidence of complications with prophylaxis using low-molecular-weight heparin (LMWH) enoxaparin in a population after hip or knee joint replacement.
News Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Administering an infusion of activated prothrombin complex concentrate (aPCC) at the standardized rate of 2 U/kg/min can be time-consuming, especially when repeated applications are needed. The authors of the recently published multicenter study cited below focused on the safety and tolerability of reducing the infusion volume by 50% and increasing the infusion rate to 4 and 10 U/kg/min.
News Romiplostim in Newly Diagnosed or Persistent ITP
Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.
News Debate on Sepsis Biomarkers 'on Blood'
Sepsis represents a major cause of death from infectious diseases. Early identification of patients with a prognosis of sepsis is therefore crucial for their survival and prognosis. In addition to traditional biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT), other markers are being sought that could be used in the differential diagnosis of sepsis. This issue was also addressed at a symposium organized by Beckmann Coulter, which took place on April 28, 2022, as part of the Colours of Sepsis congress in Ostrava.
News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension
A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.
News Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?
Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and North America. However, this field is experiencing very dynamic developments, both in terms of diagnosis and therapy. The biggest changes have occurred in treatment regimens, and recommendations for the therapy of relapsed or refractory CLL have also changed. Innovations have also emerged in prognostic examinations. As part of the update to the 'Red Book' by the Czech Hematological Society ČLS JEP (CHS), fresh recommendations concerning this disease were published in October 2023.
News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
News Current and Future Possibilities for Influencing Immune Thrombocytopenia
The possibilities for treating immune thrombocytopenia (ITP) are quite broad today, with a major advancement for many patients being the advent of thrombopoietin receptor agonists. However, for some patients, optimal treatment is still not available, and their hope lies in further research.